CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 266 enrolled
Drug / intervention
Placebo +4 moredrug
Likely dose
150 mg PF-04991532from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01336738
NCT01336738Phase 2Completed
CompareCT.gov

A 12-Week, Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-04991532 And Sitagliptin In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin

Pfizer·interventional·Posted Apr 18, 2011·Updated Aug 6, 2013

In Brief

A Phase 2 clinical trial evaluating Placebo, 150 mg PF-04991532, and 3 other interventions for Diabetes, Type 2. Completed, enrolled 266 participants across 44 sites in 7 countries.

Detailed Summary

B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Type 2
CountriesCanada, Hungary, Mexico, Slovakia, South Korea, Taiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 18, 2011
Enrollment StartJun 1, 2011
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.2 years ago

Interventions

Placebodrug

Tablets (n=6), 0 mg, once daily for 84 days

150 mg PF-04991532drug

Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days

450 mg PF-04991532drug

Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days

750 mg PF-04991532drug

Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days

Sitagliptin 100 mgdrug

Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days